Clinical trial · Observational
High-dose Etoposide Could Discriminate Patients With Refractory/Relapsed Lymphoma Benefit From APBSCT
2008 WHO Myeloid and Lymphocytic Tumor Diagnostic Criteria
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
patients with refractory /relapsed lymphoma received high-dose etoposide for hematopoietic stem cell (HSC) mobilization.All patients received high-dose etoposide 20-25 mg/kg/d intravenously for two consecutive days followed by rhG-CSF10ug/kg/day subcutaneously at 48 hours after chemotherapy; rhG-CSF was continued until the end of harvesting for HSCs/HPCs. Peripheral blood counts were performed daily for all patients following the initiating of rhG-CSF. Leukapheresis was performed when peripheral blood white blood count exceeded 4×109/L with blood cell The harvested cells reached at least 2\*108/kg for mononuclear cells and/or 2\*106/kg for CD34+ cells with once to twice leukapheresis. The final product was kept frozen in liquid nitrogen.Auto-PBSCT
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| high-dose etoposide | Drug | Etoposide | ALIAS |
Design
Arms and outcomes
Arms (2)
- label
- Disease status at mobilization PR
- interventionNames
- Drug: high-dose etoposide
- label
- Disease status at mobilization PD
- interventionNames
- Drug: high-dose etoposide
Primary outcomes (3)
- measure
- death
- timeFrame
- 10 years
- description
- death
- measure
- CR
- timeFrame
- 10 years
- description
- Complete response
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * relapsed/refractory lymphoma ,siut APBSCT Exclusion Criteria: * bone marrow without involvement by lymphoma cells
References
Publications (0)
Data not yet available